Longitudinal molecular trajectories of diffuse glioma in adults.

  • NORLUX Neuro-Oncology Laboratory
December 01, 2019 By:
  • Barthel FP
  • Johnson KC
  • Varn FS
  • Moskalik AD
  • Tanner G
  • Kocakavuk E
  • Anderson KJ
  • Abiola O
  • Aldape K
  • Alfaro KD
  • Alpar D
  • Amin SB
  • Ashley DM
  • Bandopadhayay P
  • Barnholtz-Sloan JS
  • Beroukhim R
  • Bock C
  • Brastianos PK
  • Brat DJ
  • Brodbelt AR
  • Bruns AF
  • Bulsara KR
  • Chakrabarty A
  • Chakravarti A
  • Chuang JH
  • Claus EB
  • Cochran EJ
  • Connelly J
  • Costello JF
  • Finocchiaro G
  • Fletcher MN
  • French PJ
  • Gan HK
  • Gilbert MR
  • Gould PV
  • Grimmer MR
  • Iavarone A
  • Ismail A
  • Jenkinson MD
  • Khasraw M
  • Kim H
  • Kouwenhoven MCM
  • LaViolette PS
  • Li M
  • Lichter P
  • Ligon KL
  • Lowman AK
  • Malta TM
  • Mazor T
  • McDonald KL
  • Molinaro AM
  • Nam DH
  • Nayyar N
  • Ng HK
  • Ngan CY
  • Niclou SP
  • Niers JM
  • Noushmehr H
  • Noorbakhsh J
  • Ormond DR
  • Park CK
  • Poisson LM
  • Rabadan R
  • Radlwimmer B
  • Rao G
  • Reifenberger G
  • Sa JK
  • Schuster M
  • Shaw BL
  • Short SC
  • Smitt PAS
  • Sloan AE
  • Smits M
  • Suzuki H
  • Tabatabai G
  • Van Meir EG
  • Watts C
  • Weller M
  • Wesseling P
  • Westerman BA
  • Widhalm G
  • Woehrer A
  • Yung WKA
  • Zadeh G
  • Huse JT
  • De Groot JF
  • Stead LF
  • Verhaak RGW
  • Glass Consortium.

The evolutionary processes that drive universal therapeutic resistance in adult patients with diffuse glioma remain unclear(1,2). Here we analysed temporally separated DNA-sequencing data and matched clinical annotation from 222 adult patients with glioma. By analysing mutations and copy numbers across the three major subtypes of diffuse glioma, we found that driver genes detected at the initial stage of disease were retained at recurrence, whereas there was little evidence of recurrence-specific gene alterations. Treatment with alkylating agents resulted in a hypermutator phenotype at different rates across the glioma subtypes, and hypermutation was not associated with differences in overall survival. Acquired aneuploidy was frequently detected in recurrent gliomas and was characterized by IDH mutation but without co-deletion of chromosome arms 1p/19q, and further converged with acquired alterations in the cell cycle and poor outcomes. The clonal architecture of each tumour remained similar over time, but the presence of subclonal selection was associated with decreased survival. Finally, there were no differences in the levels of immunoediting between initial and recurrent gliomas. Collectively, our results suggest that the strongest selective pressures occur during early glioma development and that current therapies shape this evolution in a largely stochastic manner.

2019 Dec. Nature.576(7785):112-120. Epub 2019 Nov 20.
Other information